Antihyperglycemic agents such as DPP-4 inhibitors (e.g., teneligliptin) and GLP-1 receptor agonists (e.g., liraglutide, semaglutide) have been shown to lessen the severity of neuropathy by improving nerve conduction and reducing oxidative stress [62]. The gene discussed is GLP1R; the disease is neuropathy.